Biosimilar insulins – potential to provide safe, high quality and cost efficient treatment options

Diabetes disease

An estimated 463 million people were suffering from diabetes worldwide in 2019. Type 2 diabetes begins with insulin resistance and counts for 90% of cases. Type 1 diabetes results from failure of the pancreas to produce enough insulin due to loss of beta cells.

The main goal of diabetes management as far as possible is to restore carbohydrate metabolism to a normal state, to avoid abnormal high concentration of a sugar called glucose in the blood and to minimize chronic complications. When insulin resistance is the case for diabetes it can also be managed with dietary modifications and exercise. For type 1 diabetes this is achieved with injections or an insulin pump. 

Insulin Glargine-yfgn

Insulin glargine-yfgn is a long-acting insulin, used in the management of type I and type II diabetes. It differs from human insulin by replacing asparagine with glycine in position 21 of the A-chain and by carboxy-terminal extension of B-chain by 2 arginine residues.

Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product approved in the U.S. for the treatment of diabetes. Approval of these insulin products can provide patients with additional safe, high-quality and potentially cost-effective options for treating diabetes.

VelaLabs supports clients with the analytical characterization of different insulin products

USP/EP compliant assays as well as tailor made adaptions can be used to support your product development up to release for clinical and market purpose.

Read more about biomolecules HERE.
More information from International Diabetes Organization HERE.

With our services in analysis and characterization of biomolecules our experts are looking forward to answering your questions. 

Contact us – we are looking forward to supporting your analysis needs

velabd@vela-labs.at  I   +43 189 059 7911.